Department of Molecular Biology and Genetics, Science Faculty, Dicle University, Diyarbakir 21280, Turkey.
First Department of Pediatrics, National and Kapodistrian University of Athens, Thivon & Levadeias 8, Goudi, 11527 Athens, Greece.
Int J Mol Sci. 2024 Feb 11;25(4):2173. doi: 10.3390/ijms25042173.
Epithelial-mesenchymal transition (EMT) is a metabolic process that confers phenotypic flexibility to cells and the ability to adapt to new functions. This transition is critical during embryogenesis and is required for the differentiation of many tissues and organs. EMT can also be induced in advanced-stage cancers, leading to further malignant behavior and chemotherapy resistance, resulting in an unfavorable prognosis for patients. Although EMT was long considered and studied only in solid tumors, it has been shown to be involved in the pathogenesis of hematological malignancies, including acute leukemias. Indeed, there is increasing evidence that EMT promotes the progression of acute leukemias, leading to the emergence of a more aggressive phenotype of the disease, and also causes chemotherapy resistance. The current literature suggests that the levels and activities of EMT inducers and markers can be used to predict prognosis, and that targeting EMT in addition to conventional therapies may increase treatment success in acute leukemias.
上皮-间充质转化(EMT)是一种赋予细胞表型灵活性和适应新功能的代谢过程。该转化在胚胎发生过程中至关重要,并且是许多组织和器官分化所必需的。EMT 也可以在晚期癌症中诱导,导致进一步的恶性行为和化疗耐药,从而导致患者预后不良。尽管 EMT 长期以来仅被认为和研究存在于实体瘤中,但现已表明其参与了包括急性白血病在内的血液恶性肿瘤的发病机制。事实上,越来越多的证据表明 EMT 促进了急性白血病的进展,导致疾病出现更具侵袭性的表型,并导致化疗耐药。目前的文献表明,EMT 诱导剂和标志物的水平和活性可用于预测预后,并且除了常规疗法之外靶向 EMT 可能会增加急性白血病的治疗成功率。